恩威医药
(301331)
| 流通市值：21.06亿 | | | 总市值：21.12亿 |
| 流通股本：1.03亿 | | | 总股本：1.03亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 374,578,793.61 | 175,328,944.36 | 900,771,087.12 | 636,853,560 |
| 营业总成本 | 363,426,013.64 | 163,762,300.69 | 842,272,742.13 | 603,849,773.06 |
| 其他经营收益 | | | | |
| 营业利润 | 15,347,209.25 | 14,090,150.86 | 62,359,043.7 | 43,356,667.76 |
| 利润总额 | 17,954,539.98 | 13,882,903.43 | 64,163,756.05 | 43,187,561.47 |
| 净利润 | 16,022,873.88 | 12,504,732.32 | 51,944,936.65 | 36,584,661.67 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | 0 | - |
| 综合收益总额 | 16,022,873.88 | 12,504,732.32 | 51,944,936.65 | 36,584,661.67 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 856,468,554.85 | 920,020,713.92 | 975,462,846.46 | 937,260,557.13 |
| 非流动资产: | | | | |
| 非流动资产合计 | 581,200,146.73 | 578,863,880.52 | 575,199,716.74 | 559,448,194.4 |
| 资产总计 | 1,437,668,701.58 | 1,498,884,594.44 | 1,550,662,563.2 | 1,496,708,751.53 |
| 流动负债: | | | | |
| 流动负债合计 | 203,439,252.01 | 390,258,378.95 | 454,989,723.03 | 211,216,454.12 |
| 非流动负债: | | | | |
| 非流动负债合计 | 212,359,240.99 | 22,413,539.69 | 22,866,715.43 | 201,844,022.66 |
| 负债合计 | 415,798,493 | 412,671,918.64 | 477,856,438.46 | 413,060,476.78 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,021,870,208.58 | 1,086,212,675.8 | 1,072,806,124.74 | 1,083,648,274.75 |
| 股东权益合计 | 1,021,870,208.58 | 1,086,212,675.8 | 1,072,806,124.74 | 1,083,648,274.75 |
| 负债和股东权益合计 | 1,437,668,701.58 | 1,498,884,594.44 | 1,550,662,563.2 | 1,496,708,751.53 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 426,764,779.2 | 180,047,207.88 | 830,274,501.92 | 617,940,375 |
| 经营活动现金流出小计 | 360,700,253.57 | 183,539,527.9 | 720,681,639.81 | 541,738,339.99 |
| 经营活动产生的现金流量净额 | 66,064,525.63 | -3,492,320.02 | 109,592,862.11 | 76,202,035.01 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 859,120,925.44 | 401,229,699.93 | 1,672,288,578.5 | 1,267,294,447.06 |
| 投资活动现金流出小计 | 815,645,761.21 | 422,926,404.29 | 1,751,116,936.08 | 1,346,711,793.66 |
| 投资活动产生的现金流量净额 | 43,475,164.23 | -21,696,704.36 | -78,828,357.58 | -79,417,346.6 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 200,000,000 | - | 10,774,174.77 | - |
| 筹资活动现金流出小计 | 292,059,474.65 | 36,388,140.57 | 32,463,084.27 | 26,442,128.13 |
| 筹资活动产生的现金流量净额 | -92,059,474.65 | -36,388,140.57 | -21,688,909.5 | -26,442,128.13 |
| 汇率变动对现金及现金等价物的影响 | -186.24 | -93.5 | -136.37 | -70.8 |
| 现金及现金等价物净增加额 | 17,480,028.97 | -61,577,258.45 | 9,075,458.66 | -29,657,510.52 |
| 期末现金及现金等价物余额 | 315,779,277.18 | 236,721,989.76 | 298,299,248.21 | 259,566,279.03 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 17,480,028.97 | - | 9,075,458.66 | - |